Metastatic Clinical Trial
Official title:
Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial
To explore the safety and efficacy of Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial. Meanwhile, Exploring the maximum tolerant dose or recommended II research dose of Surufatinib combined with a fixed dose of Sintilimab and Capecitabine using 3 + 3 dose climbing experiment.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | November 30, 2025 |
Est. primary completion date | November 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Histological or cytological documentation of adenocarcinoma of Small Intestine or Appendix Carcinoma. All other histological types are excluded. 2. Subjects with metastatic adenocarcinoma of Small Intestine or Appendix Carcinoma. 3. Subjects must have failed at least one line of prior treatment. 4. Progression during or within 3 months following the last administration of approved standard therapies . 4.1 Subjects an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy. 4.2 Subjects who have withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease will also be allowed into the study. 4.3 Subjects may have received prior treatment with Avastin (bevacizumab) 5. Subjects must have measurable or non measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. 6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 1. 7. Life expectancy of at least 3 months. 8. Adequate bone marrow, liver and renal function as assessed by the laboratory required by protocol. Exclusion Criteria: 1. Prior treatment with Surufatinib 2. Previously received anti-programmed death-1 (PD-1) or its ligand (PD-L1) antibody, anti-cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T- lymphocyte-associated Protein 4, CTLA-4) antibody or other drug/antibody that acts on T cell costimulation or checkpoint pathways. 3. Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)]. 4. Cardiological disease including Congestive heart failure, Unstable angina, Myocardial infarction, Cardiac arrhythmias requiring anti-arrhythmic therapy. 5. Uncontrolled hypertension. (Systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg despite optimal medical management). 6. Pleural effusion or ascites that causes respiratory compromise. Arterial or venous thrombotic or embolic events. 7. Any history of or currently known brain metastases. 8. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent. 9. Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 week. |
Country | Name | City | State |
---|---|---|---|
China | The Sixth Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | The PFS is defined as the time from the start of treatment to the date of first documented PD or death as a result of any cause, whichever occurred first. When a patient was alive and without progression, PFS was censored at the date of the last disease assessment. | 2 year | |
Secondary | Objective response rate (ORR) | The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR). | 2 year | |
Secondary | Overall Survival (OS) | OS is defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. | 2 year | |
Secondary | Disease Control Rate (DCR) | DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating) | 2 year | |
Secondary | Safety variables (Incidence of Adverse Events [Safety and Tolerability]) | Safety variables will be summarized using descriptive statistics based on adverse events collection | 2 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04333706 -
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05730673 -
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT01703585 -
Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples
|
||
Completed |
NCT01216345 -
Cetuximab + Gemox in Biliary Tract Cancer
|
Phase 2 | |
Recruiting |
NCT00509964 -
Second-Line Irinotecan vs. ILF for AGC
|
Phase 2 | |
Active, not recruiting |
NCT02069730 -
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
|
N/A | |
Completed |
NCT01745757 -
Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer
|
||
Completed |
NCT01633645 -
Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT04602117 -
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT05496686 -
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
|
Phase 1 | |
Completed |
NCT02639026 -
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
|
Phase 1 | |
Completed |
NCT01719744 -
Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT05673811 -
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT05868226 -
PRE-I-SPY Phase I/Ib Oncology Platform Program
|
Phase 1 | |
Completed |
NCT00498797 -
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
|
Phase 2 | |
Completed |
NCT00507091 -
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
|
Phase 1 | |
Recruiting |
NCT06007937 -
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01974752 -
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
|
Phase 3 |